October 4th 2024
The researchers identified 32 proteins associated with rapid declines in lung function.
September 17th 2024
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
New Study Points Out Doubling of Hospitalizations and Healthcare Costs for PH-ILD
August 5th 2024A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.
Read More
New Study Reveals How Non-Coding FOXF1 Gene Deletions Lead to Fatal Lung Disease in Newborns
June 24th 2024A new study looked to show how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions can lead to a rare, lethal, genetic lung disease which causes respiratory failure in many newborns and infants.
Read More
Tackling Tuberculosis Head on Through Screening, Further Preventative Measures
Published: June 3rd 2024 | Updated: June 3rd 2024In 2022 alone, an estimated 10.6 million new TB cases were reported, mainly in low-income regions, highlighting the urgent need for further efforts in TB prevention and control.
Read More
The Relationship Between ILD and MDA5 Antibody-Positive DM
May 2nd 2024Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.
Read More